US 12,440,173 B2
Displays for a medical device
Wesley Scott Harper, Alameda, CA (US); Annie C. Tan, Redwood City, CA (US); Timothy Christian Dunn, San Francisco, CA (US); Mark Kent Sloan, Redwood City, CA (US); Kenneth J. Doniger, Menlo Park, CA (US); Michael Love, Pleasanton, CA (US); Phillip Yee, San Francisco, CA (US); Gary Alan Hayter, Oakland, CA (US); R. Curtis Jennewine, Portland, OR (US); and Glenn Howard Berman, Alameda, CA (US)
Assigned to ABBOTT DIABETES CARE INC., Alameda, CA (US)
Filed by ABBOTT DIABETES CARE INC., Alameda, CA (US)
Filed on Aug. 18, 2022, as Appl. No. 17/890,810.
Application 17/890,810 is a continuation of application No. 17/720,986, filed on Apr. 14, 2022.
Application 17/890,810 is a continuation of application No. 17/720,947, filed on Apr. 14, 2022.
Application 17/890,810 is a continuation of application No. 17/720,969, filed on Apr. 14, 2022.
Application 17/720,986 is a continuation of application No. 17/580,593, filed on Jan. 20, 2022.
Application 17/580,593 is a continuation of application No. 17/107,097, filed on Nov. 30, 2020, granted, now 11,241,175, issued on Feb. 8, 2022.
Application 17/107,097 is a continuation of application No. 17/067,443, filed on Oct. 9, 2020, granted, now 10,918,342, issued on Feb. 16, 2021.
Application 17/067,443 is a continuation of application No. 16/902,111, filed on Jun. 15, 2020, granted, now 10,881,355, issued on Jan. 5, 2021.
Application 16/902,111 is a continuation of application No. 16/664,083, filed on Oct. 25, 2019, granted, now 10,772,572, issued on Sep. 15, 2020.
Application 16/664,083 is a continuation of application No. 16/181,081, filed on Nov. 5, 2018, granted, now 10,456,091, issued on Oct. 29, 2019.
Application 16/181,081 is a continuation of application No. 15/808,918, filed on Nov. 10, 2017, granted, now 10,123,752, issued on Nov. 13, 2018.
Application 15/808,918 is a continuation of application No. 15/377,989, filed on Dec. 13, 2016, granted, now 9,814,416, issued on Nov. 14, 2017.
Application 15/377,989 is a continuation of application No. 14/938,840, filed on Nov. 11, 2015, granted, now 9,549,694, issued on Jan. 24, 2017.
Application 14/938,840 is a continuation of application No. 14/457,066, filed on Aug. 11, 2014, granted, now 9,186,113, issued on Nov. 17, 2015.
Application 14/457,066 is a continuation of application No. 13/970,556, filed on Aug. 19, 2013, granted, now 8,816,862, issued on Aug. 26, 2014.
Application 13/970,556 is a continuation of application No. 12/871,901, filed on Aug. 30, 2010, granted, now 8,514,086, issued on Aug. 20, 2013.
Claims priority of provisional application 61/297,625, filed on Jan. 22, 2010.
Claims priority of provisional application 61/247,541, filed on Sep. 30, 2009.
Claims priority of provisional application 61/238,672, filed on Aug. 31, 2009.
Claims priority of provisional application 61/238,657, filed on Aug. 31, 2009.
Prior Publication US 2022/0401041 A1, Dec. 22, 2022
Int. Cl. A61B 5/00 (2006.01); A61B 5/145 (2006.01); G01N 33/487 (2006.01); G16H 20/17 (2018.01); G16H 40/63 (2018.01); G16Z 99/00 (2019.01)
CPC A61B 5/7445 (2013.01) [A61B 5/14 (2013.01); A61B 5/145 (2013.01); A61B 5/14532 (2013.01); A61B 5/7275 (2013.01); A61B 5/7282 (2013.01); A61B 5/7425 (2013.01); A61B 5/743 (2013.01); A61B 5/7435 (2013.01); A61B 5/746 (2013.01); A61B 5/748 (2013.01); A61B 2560/045 (2013.01); A61B 2562/0295 (2013.01); G01N 33/48785 (2013.01); G01N 33/48792 (2013.01); G16H 20/17 (2018.01); G16H 40/63 (2018.01); G16Z 99/00 (2019.02)] 30 Claims
OG exemplary drawing
 
1. One or more non-transitory computer-readable mediums comprising instructions which, when executed by processing circuitry, are configured to cause the processing circuitry to:
receive, from an on-skin glucose sensor control unit, a plurality of glucose levels that were determined based at least in part on factory-determined calibration measurements and signals from an electrochemical transcutaneous glucose sensor connected to the on-skin sensor control unit, wherein a portion of the glucose sensor is in contact with the user's interstitial fluid;
determine a current sensor life representing a first time period until expiration of a lifetime of the glucose sensor;
determine a grace period representing a second time period until the glucose sensor needs to be replaced;
output, on a display, a plurality of graphical user interface display screens comprising:
a first display screen that dynamically and simultaneously displays current glucose information, a trend information icon, and a line graph, wherein:
the displayed current glucose information indicates the most recently received glucose level, and a color scheme is used in connection with the displayed current glucose information, wherein the color scheme changes based upon a relationship between the displayed current glucose information and one or more glucose thresholds;
the displayed trend information icon indicates a rate of change associated with the glucose information and a direction of the change; and
the displayed line graph indicates a plurality of the received glucose levels and comprises a y-axis corresponding to the received glucose levels displayed on the line graph and an x-axis corresponding to time; and
a second display screen that displays an indication of the current sensor life, an indication of the date and time of expiry of the glucose sensor, and information associated with the grace period;
a third display screen that displays and enables the user to enter events; and
a fourth display screen that displays statistics information for a user-selectable third time period covering a plurality of the received glucose values, wherein the fourth screen comprises:
a displayed graphic indicative of respective percentages of time the received glucose values from within the user-selectable third time period were within or outside of one or more glucose ranges defined by one or more of the glucose thresholds, wherein the graphic is color coded such that a plurality of displayed colors each corresponds to a respective relationship between one of the percentages of time and one of the glucose thresholds; and
a displayed indication of the average of the received glucose values from within the user-selectable third time period.